

# Canada's Premiere Virtual Cardiovascular Symposium

Aimed at cardiovascular specialists, CardioMet'26 will highlight topics of major interest or controversy across six therapeutic themes. Featuring world-class faculty, interactivity, and cutting edge science, CardioMet'26 will be unlike any other cardiovascular conference in Canada.

## JANUARY 23 and 30, 2026

12:00 - 6:15 pm EST

### Program Themes

#### • 23<sup>rd</sup> JANUARY 2026

- INFLAMMATION
- PREVENTION
- CORONARY DISEASE

#### • 30<sup>th</sup> JANUARY 2026

- ARRHYTHMIA
- CARDIOMYOPATHIES
- HEART FAILURE

## Register Now!

### ACCREDITATION

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the University of Calgary Office of Continuing Medical Education and Professional Development. This activity has been approved for a maximum of 11.0 hours (credits are automatically calculated).

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™.

# CardioMet<sup>26</sup>

### Scientific Planning Committee



**Margot Davis**

MD, MSc, FRCP, FCCS  
University of British Columbia



**Anique Ducharme**

MD, MSc, FRCP, FCCS  
Montreal Heart Institute



**Milan Gupta**

MD, FRCPC, FCCS, CPC(HC)  
University of Toronto



**Jay Udell**

MD, MPH, FRCPC  
Toronto General Hospital

### Overall Learning Objectives:

- ✓ Discuss the latest advances in cardiovascular risk factor management and prevention
- ✓ Explain new developments in the management of heart failure, cardiomyopathies and arrhythmia
- ✓ Explore advances in the role of inflammation in cardiovascular disease

### Registration

Visit: [www.ccrnmd.com](http://www.ccrnmd.com)

For inquiries regarding this program, please contact [info@ccrnmd.com](mailto:info@ccrnmd.com).



 **CCRN**  
Collaborative CME and Research Network

# PROGRAM AGENDA

Friday, January 23, 2026



CardioNet<sup>26</sup>

 CCRN  
Collaborative CME and Research Network

| Time             | Topic  | Faculty                                      |
|------------------|--|--|
| 12:00 - 12:10    | Welcome and opening remarks                                    |  |
| <b>THEME ONE</b> | <b>INFLAMMATION</b>  | <b>Moderators: Milan Gupta and Jay Udell</b> |
| 12:10 - 12:15    | Introductions  |  |
| 12:15 - 12:33    | Pericarditis: Acute and Chronic                                | <b>Kevin Boczar</b>                          |
| 12:33 - 12:51    | Myocarditis: Diagnosis and Management                          | <b>Adriana Luk</b>                           |
| 12:51 - 1:09     | Should immunization be routine in secondary prevention?        | <b>Kim Connelly</b>                          |
| 1:09 - 1:27      | Inflammation as a treatment target in chronic coronary disease | <b>Paul Ridker</b>                           |
| 1:27 - 1:51      | DISCUSSION   |  |

## • Learning Objectives

- Evaluate the diagnosis and management of acute and chronic pericarditis
- Apply evidence-based approaches to the diagnosis and management of myocarditis
- Assess the role of immunization in secondary prevention of cardiovascular disease
- Evaluate evidence on targeting inflammation in chronic coronary disease and its implications for patient management

|                  |  |  |
|------------------|--|--|
| <b>THEME TWO</b> | <b>PREVENTION</b>                          | <b>Moderators: Milan Gupta and Jay Udell</b> |
| 1:51 - 1:56      | Introductions                              |  |
| 1:56 - 2:14      | How to manage resistant hypertension       | <b>Raj Padwal</b>                            |
| 2:14 - 2:32      | Timely achievement of LDL targets post-ACS | <b>Shamir Mehta</b>                          |
| 2:32 - 2:50      | Bempedoic acid: the new kid on the block   | <b>Milan Gupta</b>                           |
| 2:50 - 3:08      | Management strategies for elevated Lp(a)   | <b>George Thanassoulis</b>                   |
| 3:08 - 3:32      | DISCUSSION                                 |  |

## • Learning Objectives

- Implement evidence-based strategies for the evaluation and management of resistant hypertension
- Apply guidelines and strategies to achieve LDL cholesterol targets promptly in patients following acute coronary syndrome
- Evaluate the clinical role, efficacy, and safety of bempedoic acid for cardiovascular risk reduction
- Assess current and emerging strategies for the management of elevated lipoprotein(a) to reduce cardiovascular risk

3:32 - 4:00 **REFRESHMENT BREAK**

## KEYNOTE ADDRESS

|             |  |                        |
|-------------|--|------------------------|
| 4:00 - 4:02 | Introductions  |                        |
| 4:02 - 4:22 | Should we screen for and act on subclinical atherosclerosis? | <b>Valentin Fuster</b> |
| 4:22 - 4:32 | DISCUSSION   |                        |

## • Learning Objectives

- Identify patients who may benefit from subclinical atherosclerosis screening and implement evidence-based strategies to reduce cardiovascular risk

|                    |   |  |
|--------------------|---|--|
| <b>THEME THREE</b> | <b>CORONARY DISEASE</b>                             | <b>Moderators: Milan Gupta and Jay Udell</b> |
| 4:32 - 4:37        | Introductions                                       |  |
| 4:37 - 4:55        | Is cardiac rehab still relevant?                    | <b>Paul Oh</b>                               |
| 4:55 - 5:13        | What to do with non-specific troponin elevation?    | <b>Allan Jaffe</b>                           |
| 5:13 - 5:31        | DAPT Post-ACS/PCI: How many drugs and for how long? | <b>Graham Wong</b>                           |
| 5:31 - 5:49        | The role of beta-blockers post-MI                   | <b>Sripal Bangalore</b>                      |
| 5:49 - 6:13        | DISCUSSION  |  |

## • Learning Objectives

- Evaluate the evidence for cardiac rehabilitation and integrate its role into contemporary management of patients with coronary disease
- Interpret non-specific troponin elevations and apply evidence-based strategies to guide further evaluation and management
- Determine optimal dual antiplatelet therapy strategies for patients following ACS or PCI
- Implement evidence-based strategies for prescribing beta-blockers post-myocardial infarction

6:13 - 6:15 **MEETING CLOSE**



| Time  | Topic   | Faculty   |
|---|---|---|
| 12:00 - 12:10   | Welcome and opening remarks   |   |
| <b>THEME ONE</b>  | <b>ARRHYTHMIA</b>   | <b>Moderators: Margot Davis and Milan Gupta</b>     |
| 12:10 - 12:15   | Introductions   |   |
| 12:15 - 12:33   | Is there still a role for antiarrhythmic drugs for AF?                                  | Peter Kowey   |
| 12:33 - 12:51   | AF management in heart failure  | Jason Andrade                                       |
| 12:51 - 1:09  | Advances in pacemaker/CRT technology  | Andrew Ha   |
| 1:09 - 1:27   | Sudden cardiac death in athletes  | Nate Moulson  |
| 1:27 - 1:51   | DISCUSSION  |   |
| <b>• Learning Objectives</b>  |   |   |
| <ul style="list-style-type: none"> <li>Assess the role of antiarrhythmic drugs in atrial fibrillation management</li> <li>Apply evidence-based strategies to optimize atrial fibrillation management in patients with heart failure</li> <li>Evaluate recent advances in pacemaker and cardiac resynchronization therapy (CRT) technology</li> <li>Identify risk factors for sudden cardiac death in athletes</li> </ul>  |   |   |
| <b>THEME TWO</b>  | <b>CARDIOMYOPATHIES</b>   | <b>Moderators: Margot Davis and Anique Ducharme</b> |
| 1:51 - 1:56   | Introductions   |   |
| 1:56 - 2:14   | Takotsubo cardiomyopathy: recognition and management                                    | Antonio Abbate                                      |
| 2:14 - 2:32   | ATTR: moving from specialized centres to the cardiology clinic                          | Margot Davis  |
| 2:32 - 2:50   | Hypertrophic cardiomyopathy: When to use new drugs or consider septal reduction therapy | Martin Maron  |
| 2:50 - 3:08   | Cardiomyopathies in pregnancy   | Jasmine Grewal                                      |
| 3:08 - 3:32   | DISCUSSION  |   |
| <b>• Learning Objectives</b>  |   |   |
| <ul style="list-style-type: none"> <li>Identify Takotsubo cardiomyopathy and apply evidence-based strategies for its management and follow-up</li> <li>Recognize transthyretin amyloid cardiomyopathy (ATTR) and integrate its diagnosis and management into general cardiology practice</li> <li>Determine when to initiate novel pharmacologic therapies or refer for septal reduction in patients with hypertrophic cardiomyopathy</li> <li>Assess and manage cardiomyopathies in pregnant patients, applying evidence-based strategies to optimize maternal and fetal outcomes</li> </ul> |   |   |
| 3:32 - 4:00   | <b>REFRESHMENT BREAK</b>  |   |
| <b>KEYNOTE ADDRESS</b>  |   |   |
| 4:00 - 4:02   | Introductions   |   |
| 4:02 - 4:22   | Is it time for cardiology to take ownership of obesity management?                      | Darren McGuire                                      |
| 4:22 - 4:32   | DISCUSSION  |   |
| <b>• Learning Objectives</b>  |   |   |
| <ul style="list-style-type: none"> <li>Apply evidence-based obesity management strategies to optimize cardiovascular outcomes and reduce patient risk</li> </ul>  |   |   |
| <b>THEME THREE</b>  | <b>HEART FAILURE</b>  | <b>Moderators: Margot Davis and Anique Ducharme</b> |
| 4:32 - 4:37   | Introductions   |   |
| 4:37 - 4:55   | Detecting pulmonary hypertension on echo – when to refer                                | John Granton  |
| 4:55 - 5:13   | Guideline update for HFrEF: the role of MRA's   | Muthiah Vaduganathan                                |
| 5:13 - 5:31   | HFrEF: How to optimize GDMT in a busy clinic  | Stephanie Poon                                      |
| 5:31 - 5:49   | Advanced heart failure: What next?  | Brian Clarke  |
| 5:49 - 6:13   | DISCUSSION  |   |
| <b>• Learning Objectives</b>  |   |   |
| <ul style="list-style-type: none"> <li>Identify echocardiographic signs of pulmonary hypertension and determine when specialist referral is indicated</li> <li>Apply guideline recommendations for the use of mineralocorticoid receptor antagonists in the management of HFrEF</li> <li>Implement strategies to optimize guideline-directed medical therapy for HFrEF efficiently</li> <li>Assess emerging medical and device therapies for advanced heart failure</li> </ul>  |   |   |
| 6:13 - 6:15   | <b>MEETING CLOSE</b>  |   |

## Registration

Visit: [www.ccrnmd.com](http://www.ccrnmd.com)

For inquiries regarding this program,  
please contact [info@ccrnmd.com](mailto:info@ccrnmd.com).



# Canada's Premiere Virtual Cardiovascular Symposium

Aimed at cardiovascular specialists, CardioMet'26 will highlight topics of major interest or controversy across six therapeutic themes. Featuring world-class faculty, interactivity, and cutting edge science, CardioMet'26 will be unlike any other cardiovascular conference in Canada.

**JANUARY  
23 and 30, 2026**

**12:00 – 6:15 pm EST**

## Program Themes

### • **23<sup>rd</sup> JANUARY 2026**

- INFLAMMATION
- PREVENTION
- CORONARY DISEASE

### • **30<sup>th</sup> JANUARY 2026**

- ARRHYTHMIA
- CARDIOMYOPATHIES
- HEART FAILURE

**Register Now!**



## SPONSORS

This program has received an educational grant or in-kind support from:

**Gold:** Amgen, AstraZeneca, Bayer, GSK, Merck, Novartis, Novo Nordisk

**Silver:** HLS Therapeutics, Pfizer

**Bronze:** Alnylam Pharmaceuticals, Bristol Myers Squibb, Eli Lilly

## Registration

Visit: [www.ccrnmd.com](http://www.ccrnmd.com)

For inquiries regarding this program, please contact [info@ccrnmd.com](mailto:info@ccrnmd.com).

